Key result
Platelet-mediated inflammatory pathways contribute to atherogenesis and operate despite the wide use of platelet-inhibiting drugs, underscoring the need for new targeted therapeutic tools.
Highlights the role of platelets as inflammatory mediators in atherosclerosis and the need for novel therapies targeting platelet-mediated inflammation.
Answers are grounded in this paper and cite their sources.
Does not support practice changes; leaves open whether targeted anti-inflammatory platelet therapies will improve atherosclerotic outcomes.
Several studies suggest an important role for platelets in atherogenesis, not only as mediators of thrombus formation, but also as inducers of inflammation. Several lines of evidence indicate that platelets are potent inflammatory cells that induce inflammatory responses in adjacent cells such as leukocytes and endothelial cells. Platelets may also themselves respond to inflammatory mediators produced by these neighboring cells. These platelet-mediated inflammatory pathways contribute to atherogenesis in both the early and late stage of the process. The bidirectional interaction between platelets and other cells may also be involved in the nonresolving inflammation characterizing atherosclerosis. In patients with atherosclerotic disorders, platelet-mediated inflammation appears to be operating in spite of the wide use of platelet-inhibiting drugs. This underscores the need for new therapeutic tools that more specifically target the pathways in platelet-mediated inflammation.
No takes yet. Share an insight, caveat, or question.
Aukrust et al. (2010) conducted a review in Atherosclerosis. Platelet-mediated inflammation was evaluated. Platelet-mediated inflammatory pathways contribute to atherogenesis and operate despite the wide use of platelet-inhibiting drugs, underscoring the need for new targeted therapeutic tools.
Synapse has enriched 10 related papers. Consider them for comparative context: